JP6153613B2 - 乳がん治療を決定する方法 - Google Patents

乳がん治療を決定する方法 Download PDF

Info

Publication number
JP6153613B2
JP6153613B2 JP2015528457A JP2015528457A JP6153613B2 JP 6153613 B2 JP6153613 B2 JP 6153613B2 JP 2015528457 A JP2015528457 A JP 2015528457A JP 2015528457 A JP2015528457 A JP 2015528457A JP 6153613 B2 JP6153613 B2 JP 6153613B2
Authority
JP
Japan
Prior art keywords
breast cancer
ratio
cells
enzalutamide
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015528457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529327A (ja
JP2015529327A5 (cg-RX-API-DMAC7.html
Inventor
モウシャンタット，ジェニファー，リッチャー
Original Assignee
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート, ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート filed Critical ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート
Publication of JP2015529327A publication Critical patent/JP2015529327A/ja
Publication of JP2015529327A5 publication Critical patent/JP2015529327A5/ja
Application granted granted Critical
Publication of JP6153613B2 publication Critical patent/JP6153613B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G01N33/57515—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015528457A 2012-08-23 2013-03-15 乳がん治療を決定する方法 Expired - Fee Related JP6153613B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692331P 2012-08-23 2012-08-23
US61/692,331 2012-08-23
PCT/US2013/031812 WO2014031164A1 (en) 2012-08-23 2013-03-15 Method for determining breast cancer treatment

Publications (3)

Publication Number Publication Date
JP2015529327A JP2015529327A (ja) 2015-10-05
JP2015529327A5 JP2015529327A5 (cg-RX-API-DMAC7.html) 2016-01-28
JP6153613B2 true JP6153613B2 (ja) 2017-06-28

Family

ID=50150282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015528457A Expired - Fee Related JP6153613B2 (ja) 2012-08-23 2013-03-15 乳がん治療を決定する方法

Country Status (7)

Country Link
US (2) US10175240B2 (cg-RX-API-DMAC7.html)
EP (1) EP2888594B1 (cg-RX-API-DMAC7.html)
JP (1) JP6153613B2 (cg-RX-API-DMAC7.html)
AU (1) AU2013306380A1 (cg-RX-API-DMAC7.html)
CA (1) CA2882621A1 (cg-RX-API-DMAC7.html)
ES (1) ES2696202T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014031164A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2739153B1 (en) 2011-07-29 2018-08-22 Medivation Prostate Therapeutics LLC Treatment of breast cancer
AU2013306380A1 (en) * 2012-08-23 2015-03-05 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
MX2017007707A (es) 2014-12-12 2018-03-06 Medivation Prostate Therapeutics Llc Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
CN113490850B (zh) * 2018-08-17 2024-12-06 基因泰克公司 用于治疗乳腺癌的诊断和治疗方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008185A (en) * 1985-11-04 1991-04-16 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear proteins
US5292638A (en) 1990-12-07 1994-03-08 The Regents Of The University Of California Method of determining functional estrogen receptors for prognosis of cancer
AU2001288213B2 (en) 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
WO2007121459A2 (en) 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of steroid receptors on circulating carcinoma cells and treatment
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures
EP2065474A1 (en) 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic response to endocrine treatment
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
AU2013306380A1 (en) 2012-08-23 2015-03-05 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment

Also Published As

Publication number Publication date
EP2888594A4 (en) 2016-04-20
US11221334B2 (en) 2022-01-11
US10175240B2 (en) 2019-01-08
JP2015529327A (ja) 2015-10-05
ES2696202T3 (es) 2019-01-14
CA2882621A1 (en) 2014-02-27
WO2014031164A1 (en) 2014-02-27
EP2888594A1 (en) 2015-07-01
EP2888594B1 (en) 2018-08-15
US20150253329A1 (en) 2015-09-10
US20190113515A1 (en) 2019-04-18
AU2013306380A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
Cochrane et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
US8470534B2 (en) Methods of predicting resistance or sensitivity to therapies for cancer
Imamura et al. Androgen receptor targeted therapies in castration‐resistant prostate cancer: bench to clinic
US11221334B2 (en) Method for determining breast cancer treatment
Rampurwala et al. Role of the androgen receptor in triple-negative breast cancer
Isikbay et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer
Chia et al. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer
Sukocheva et al. Androgens and esophageal cancer: What do we know?
Anbalagan et al. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer
Terry et al. Increased expression of class III β-tubulin in castration-resistant human prostate cancer
Johnston Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations
Mohanty et al. STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer
Chang et al. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway
Balasubramaniam et al. Aberrant BAF57 signaling facilitates prometastatic phenotypes
Chung et al. Targeting the androgen receptor signaling pathway in advanced prostate cancer
Song et al. Dihydrotestosterone enhances castration‐resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway
Karam et al. Protein kinase D1 regulates ER α‐positive breast cancer cell growth response to 17β‐estradiol and contributes to poor prognosis in patients
Xu et al. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species–dependent apoptosis
Cavalloni et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas
Bennett et al. Androgen receptor and caveolin‐1 in prostate cancer
Li et al. The small-molecule drug homoharringtonine targets HSF1 to suppress pancreatic cancer progression
US12062444B2 (en) Methods and compositions related to triple-negative breast cancer
Yang et al. Upregulation of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) mediates the reversal effect of verapamil on chemo-resistance to adriamycin of hepatocellular carcinoma
Zhang et al. Significance and mechanism of androgen receptor (AR) overexpression and AR-mTOR crosstalk in hepatocellular carcinoma
US20250281509A1 (en) Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170530

R150 Certificate of patent or registration of utility model

Ref document number: 6153613

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees